Blue JET Healthcare Ltd

NSE: BLUEJET · Pharmaceuticals · sector

₹485.60NSE close 2026-10-26

Key numbers

Market cap₹8,423 cr

Price₹485.60

52w high / low₹688 / ₹325

P/E35.8xSector median 27.9x

P/B6.2xSector median 2.9x

Book value₹78.4

Dividend yield0.25%Sector median 0.48%

ROE18.9%Sector median 11.7%

ROCE23.7%Sector median 12.3%

OPM30.6%Sector median 14.0%

Debt / equity0.00xSector median 0.16x

EV/EBITDA29.7xSector median 18.6x

Interest cover51.8x

Current ratio4.21x

Sales growth 3y–Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹376 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
Operating profit covered interest 51.8x in the last 12 months.
Promoter holding fell by 6.66 percentage points in a year, to 73.15% (2026-09-30).
Operating cash flow was below net profit in 1 of the last 3 years (FY25).
Revenue was higher than a year earlier in 0 of the last 4 quarters.
Other income was 32% of net profit in the last 12 months.
Debtor days went from 91 (FY24) to 131 (FY26).
Dividend paid in 2 of the last 3 financial years.
Price ₹485.60 on 2026-10-26: -29.5% from the 52-week high, +49.4% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹961.10 · low ₹341.30

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	208	318	340	355	165	192	235	293
EBITDA	69	124	140	121	55	47	71	98
OPM %	33.4%	39.0%	41.1%	34.1%	33.2%	24.4%	30.4%	33.5%
Other income	12	13	12	8	24	13	23	15
Net profit	58	99	110	91	52	40	64	78
EPS (₹)	3.36	5.71	6.35	5.26	3.01	2.32	3.71	4.51
Revenue YoY					-20.5%	-39.6%	-31.1%	-17.4%
Profit YoY					-10.6%	-59.4%	-41.6%	-14.2%

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY24	FY25	FY26	TTM
Revenue	712	1,030	947	886
EBITDA	219	378	294	271
Net profit	164	305	248	235
EPS (₹)	9.44	17.59	14.29	13.55
Revenue growth		+44.7%	-8.0%	-27.5%
Profit growth		+86.4%	-18.8%	-34.5%
Dividend / share (₹)	–	1.00	1.20

Compounded growth	3 years	5 years	Last 12 months
Sales	–	–	-27.5%
Net profit	–	–	-34.5%
EPS	–	–	–
Share price	–	-0.6% (2y)	-25.3%

Balance sheet

₹ cr	FY24	FY25	FY26
Shareholders' equity	845	1,133	1,360
Borrowings	0	0	0
Cash & equivalents	320	306	376
Total assets	1,059	1,418	1,641
Fixed assets	172	260	314
Capital work in progress	147	89	301
Investments	15	0	25
Receivables	177	350	339
Inventory	130	264	187
Payables	30	89	57

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY24	FY25	FY26
Cash from operations	241	46	334
Cash from investing	-264	-35	-276
Cash from financing	-2	-19	-31
Capex	173	80	0
Free cash flow	68	-34	334

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY24	FY25	FY26
ROE %	19.4%	26.9%	18.2%
ROCE %	26.1%	35.8%	24.9%
Debtor days	91	124	131
Inventory days	151	209	157
Payable days	35	70	48
Cash conversion cycle (days)	207	263	240
Working capital days	256	266	281

Shareholding

Holder	% (2026-09-30)
Promoters	73.15%
FIIs	0.82%
DIIs	7.49%
of which Mutual funds	4.10%
of which Insurance	0.73%
Public (non-institutions)	18.55%

Quarter	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Jul 2026	Sep 2026
Promoters %	86.00%	86.00%	79.81%	79.81%	79.81%	79.81%	73.15%	73.15%

Promoter group	%
Akshay Bansarilal Arora	57.55%
Shiven Akshay Arora	10.04%
Archana Akshay Arora	5.55%
Alka Rakesh Bakshi	0.00%
Amit Dhawan	0.00%
Anisha Juneja	0.00%

Public holders above 1%	%
Shamyak Investment Private Limited	2.87%
Icici Prudential Healthcare Fund	2.76%

79,390 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
BLUEJET	₹8,423 cr	35.8x	6.2x	18.9%	23.7%	30.6%	–	0.25%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-09-11	Dividend	Dividend - Rs 1.20 Per Share
2025-09-19	Dividend	Dividend - Rs 1.20 Per Share
2024-09-17	Dividend	Dividend - Re 1 Per Share
2024-09-17	Other	Annual General Meeting

Documents

Links go to the original files on the exchange website.

About the company

Manufacturing: Chemical and chemical products, pharmaceuticals, medicinal chemical, and botanical products


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	BLUEJET
BSE code	544009
ISIN	INE0KBH01020
Face value	₹2.0
Incorporated	1968-12-07
Website	https://bluejethealthcare.com
Plants (India / abroad)	8 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.